Materias dentro de su búsqueda.
Mostrando 1 - 8 Resultados de 8 Para Buscar '"Torrevieja"', tiempo de consulta: 0.20s Limitar resultados
  1. 1
    “…This work analyses the biodiversity of the Aspilota-group (Hymenoptera: Braconidae: Alysiinae) in three Mediterranean Natural parks: Natural Park of La Font Roja, Natural Park of Las Lagunas de la Mata-Torrevieja and Natural Park of La Tinença de Benifassà. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 2
    por Sierra, Javier, 1971-
    Publicado 2006
    Libro
  3. 3
    “…However, there are many other salty environments to be explored, like the natural park of Torrevieja and la Mata lagoons, salty lagoon located in Calpe city or inland salted ponds like those located in the northwest of the county. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 4
    “…Three new species are described that were captured using Malaise traps in “Tinença de Benifassà”, “Font Roja” and “Lagunas de La Mata-Torrevieja” (Spain) Natural Parks: Pseudonapomyza curvata n. sp., P. longitata n. sp., and P. sicicornis n. sp. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  5. 5
    “…RESULTS: The NVR had information on 934 (59.5%) out of 1,569 postpartum women; distribution per Health Departments was: 420 (44.9%), 161 (17.2%) and 353 (37.8%) in La Ribera, Torrevieja and Elx-Crevillent respectively. Vaccine uptake was 27.9% (n = 261). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  6. 6
  7. 7
    “…The study was carried out at four University Hospitals; Alicante, Elche, Torrevieja and Vinalopo Salud of Elche. The inclusion criteria were women aged 18–45 years old who had just delivered a singleton live baby at 38–42 weeks through vaginal delivery. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 8
    “…The Clinical Research Ethics Committee of the Hospital Quirónsalud Torrevieja approved this study. Results: The inter-individual variability in the first cycle and in the last monitored cycle was 46.2% and 44.0% for erlotinib, 48.9 and 50.8% for imatinib, 60.7% and 56.0% for lapatinib and 89.7% and 72.5% for sorafenib. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS